title: Validation of cytogenetic-based risk stratification in primary myelofibrosis.
authors.forename: Elisa
authors.initials: E
authors.lastname: Rumi
authors.forename: Francesco
authors.initials: F
authors.lastname: Passamonti
authors.forename: Paolo
authors.initials: P
authors.lastname: Bernasconi
authors.forename: Luca
authors.initials: L
authors.lastname: Arcaini
authors.forename: Daniela
authors.initials: D
authors.lastname: Pietra
authors.forename: Chiara
authors.initials: C
authors.lastname: Elena
authors.forename: Emanuela
authors.initials: E
authors.lastname: Boveri
authors.forename: Cristiana
authors.initials: C
authors.lastname: Pascutto
authors.forename: Mario
authors.initials: M
authors.lastname: Cazzola
authors.forename: Mario
authors.initials: M
authors.lastname: Lazzarino
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002869:Chromosome Aberrations; D002872:Chromosome Deletion; D020732:Cytogenetic Analysis; D005260:Female; D006801:Humans; D053614:Janus Kinase 2 / Q000502:physiology; D053208:Kaplan-Meier Estimate; D007621:Karyotyping; D008297:Male; D008875:Middle Aged; D055728:Primary Myelofibrosis / Q000453:epidemiology* / Q000235:genetics / Q000473:pathology; D011379:Prognosis; D018570:Risk Assessment; D055815:Young Adult
chemical_list: C507924:JAK2 protein, human; D053614:Janus Kinase 2